Aurinia Pharmaceuticals earnings release, May 7, 2026

Aurinia Pharmaceuticals Inc. (AUPH) · Form 8-K, Item 2.02 · Filed · SEC filing

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

ROCKVILLE, Maryland and EDMONTON, Alberta – May 7, 2026 – Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months ended March 31, 2026 and provided an update on recent business progress.

Financial Results

• Total Revenue:

For the three months ended March 31, 2026, total revenue was $77.7 million, up 24% from $62.5 million in the same period of 2025. – Net Product Sales:

For the three months ended March 31, 2026, net product sales of LUPKYNIS, the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis, were $73.6 million, up 23% from $60.0 million in the same period of 2025. – License, Collaboration and Royalty Revenue:

For the three months ended March 31, 2026, license, collaboration and royalty revenue from Aurinia’s collaboration partner, Otsuka, was $4.1 million, up 64% from $2.5 million in the same period of 2025.

• Net Income:

For the three months ended March 31, 2026, net income was $34.4 million, up 48% from $23.3 million in the same period of 2025.

• Diluted Earnings per Share:

For the three months ended March 31, 2026, diluted earnings per share was $0.25, up 56% from $0.16 in the same period of 2025.

• Cash Flows from Operating Activities:

For the three months ended March 31, 2026, cash flows from operating activities were $32.6 million, up 2408% from $1.3 million in the same period of 2025.

Cash Position

As of March 31, 2026, Aurinia had cash, cash equivalents, restricted cash and investments of $378.8 million, compared to $398.0 million at December 31, 2025. For the three months ended March 31, 2026, cash outflows from financing activities were $53.7 million, which included the repurchase of 2.5 million of the Company’ s common shares for $36.2 million and tax withholding payments related to net settlements of equity awards of $14.6 million.

2026 Total Revenue and Net Product Sales Guidance

Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, up 11% to 15% compared to 2025, and 2026 net product sales of $305 million to $315 million, up 12% to 16% compared to 2025.

“Aurinia remains steadfast in its mission to become a leading company that benefits patients suffering from autoimmune diseases,” stated Kevin Tang, Chief Executive Officer. “LUPKYNIS is emerging as a standard-of-care treatment for lupus nephritis, and aritinercept, now in clinical development for three potential indications, has therapeutic potential across a wide range of autoimmune disorders.”

About Aurinia

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS®

(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.¹

Financial statements

Income Statement

Three Months Ended — (in thousands, except per share data)

Three Months Ended – March 31, – 20262025
RevenueNet product sales73,56359,971
RevenueLicense, collaboration and royalty revenue4,1422,494
RevenueTotal revenue77,70562,465
Operating expensesCost of revenue6,5058,574
Operating expensesSelling, general and administrative22,02920,339
Operating expensesResearch and development7,4705,743
Operating expensesRestructuring1,533
Operating expensesOther expense, net2794,429
Operating expensesTotal operating expenses36,28340,618
Operating expensesIncome from operations41,42221,847
Operating expensesInterest income3,5153,569
Operating expensesInterest expense-1,012-1,067
Operating expensesNet income before income taxes43,92524,349
Operating expensesIncome tax expense9,5701,005
Operating expensesNet income34,35523,344
Earnings per shareBasic0.260.17
Earnings per shareDiluted0.250.16
Shares used in computing earnings per shareBasic132,375138,917
Shares used in computing earnings per shareDiluted137,639143,199

Balance Sheet

March 31, 2026 — (in thousands)

March 31, 2026 – (Unaudited)December 31, 2025
Current assets:Cash, cash equivalents and restricted cash41,00880,213
Current assets:Short-term investments337,775317,784
Current assets:Accounts receivable, net49,17541,454
Current assets:Inventory46,41045,690
Current assets:Prepaid expenses and deposits4,1195,746
Current assets:Other current assets1,7571,080
Current assets:Total current assets480,244491,967
Current assets:Deferred tax assets, net166,917176,194
Current assets:Finance right-of-use lease assets69,50873,865
Current assets:Intangible assets, net3,5903,761
Current assets:Operating right-of-use lease assets1,6593,596
Current assets:Property and equipment, net1,9862,111
Current assets:Other noncurrent assets9393
Current assets:Total assets723,997751,587
Current liabilities:Accounts payable2,6613,313
Current liabilities:Accrued expenses58,19666,621
Current liabilities:Finance lease liabilities, current portion16,51916,523
Current liabilities:Deferred revenue5,0363,720
Current liabilities:Operating lease liabilities, current portion1,6221,067
Current liabilities:Other current liabilities2,5222,480
Current liabilities:Total current liabilities86,55693,724
Current liabilities:Finance lease liabilities, less current portion48,18152,322
Current liabilities:Deferred revenue, less current portion12,41312,648
Current liabilities:Deferred compensation and other noncurrent liabilities6,9036,662
Current liabilities:Operating lease liabilities, less current portion2,3184,900
Current liabilities:Total liabilities156,371170,256
Shareholders' equityCommon shares — no par value, unlimited shares authorized, 130,771 and 132,323 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively1,086,6501,120,035
Shareholders' equityAdditional paid-in capital96,869111,263
Shareholders' equityAccumulated other comprehensive loss-880-599
Shareholders' equityAccumulated deficit-615,013-649,368
Shareholders' equityTotal shareholders' equity567,626581,331
Shareholders' equityTotal liabilities and shareholders' equity723,997751,587

Cash Flow

Three Months Ended March 31, — (in thousands)

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
Cash flows from operating activities:Net income34,35523,344
Adjustments to reconcile net income to cash flows from operating activities:Deferred income tax9,277
Adjustments to reconcile net income to cash flows from operating activities:Share-based compensation-866-3,409
Adjustments to reconcile net income to cash flows from operating activities:Amortization and depreciation4,8164,856
Adjustments to reconcile net income to cash flows from operating activities:Foreign exchange (gain) loss on revaluation of Monoplant finance lease liability-4161,812
Adjustments to reconcile net income to cash flows from operating activities:Net amortization of premiums and discounts on investments-2,319-2,656
Adjustments to reconcile net income to cash flows from operating activities:Other, net5812,325
Net changes in operating assets and liabilities:Accounts receivable, net-7,721-3,806
Net changes in operating assets and liabilities:Inventory-720-6,967
Net changes in operating assets and liabilities:Prepaid expenses and other current assets9506,033
Net changes in operating assets and liabilities:Accounts payable-652-974
Net changes in operating assets and liabilities:Accrued expenses and other liabilities-5,592-23,405
Net changes in operating assets and liabilities:Deferred revenue1,0814,342
Net changes in operating assets and liabilities:Operating lease liabilities-214-195
Net changes in operating assets and liabilities:Cash flows from operating activities32,5601,300
Cash flows from investing activities:Proceeds from the sale and maturities of investments109,000123,035
Cash flows from investing activities:Purchases of investments-127,041-91,986
Cash flows from investing activities:Purchases of property, equipment and intangible assets-39-17
Cash flows from investing activities:Cash flows from investing activities-18,08031,032
Cash flows from financing activities:Purchase of common shares under Share Repurchase Plan-36,165-46,921
Full release

Forward-Looking Statements

This press release contains forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable U.S. securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: LUPKYNIS net product sales, the timing of clinical study results and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com.

General Investor Inquiries ir@auriniapharma.com²

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aurinia Pharmaceuticals earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.